The capsule most shoppers pick up says 600 milligrams, and most people take one with breakfast and assume the job is done. In the lung trials that shaped what researchers believe about N-acetylcysteine, that single daily capsule is the exact regimen that failed, and the regimen that worked was the same capsule taken twice.
NAC has two lives. In much of Europe and Asia it has long been dispensed as a mucolytic, a drug meant to thin the sticky mucus that clogs the airways of people with chronic bronchitis and chronic obstructive pulmonary disease, while in the United States it sits on supplement shelves, which is why the trial record matters to anyone reading a label here. We covered the compound's basic chemistry in our primer on how the compound works, and its uneven record in psychiatry in our review of the compulsion and craving trials.
The respiratory record splits cleanly along the dose. NAC for COPD appears to reduce flare-ups at 1,200 milligrams a day and shows no benefit at 600, and a single older trial suggests it may soften winter flu without preventing infection, with everything beyond that depending on who was studied and for how long.
The first large test was BRONCUS, short for the Bronchitis Randomized on NAC Cost-Utility Study, published in The Lancet in 2005 by a team led by Marc Decramer of the University of Leuven. It enrolled 523 patients with COPD across 50 centers, randomly assigned them to 600 milligrams of NAC once daily or to placebo, and followed them for three years.
The researchers measured two things that matter most to people living with the disease, the yearly loss of lung function and the number of flare-ups, which clinicians call exacerbations. Lung function, measured as the volume a patient can force out in one second, fell by 54 milliliters a year on NAC and by 47 milliliters on placebo. Exacerbations ran at 1.25 a year on NAC against 1.29 on placebo, with a hazard ratio of 0.99.
The authors wrote their conclusion without hedging: the published abstract states that "N-acetylcysteine is ineffective at prevention of deterioration in lung function" in COPD. A subgroup analysis hinted that patients who were not using inhaled corticosteroids might have had fewer exacerbations on NAC, a signal the team flagged as something for later trials to test rather than a finding.
Two later trials in China took the same capsule and doubled the daily amount. The smaller one, HIACE, was published by Tse and colleagues in the journal Chest in 2013 and enrolled 120 patients with stable COPD, 58 of them on 600 milligrams of NAC twice daily and 62 on placebo, who were followed for a year.
Exacerbations in HIACE fell to 0.96 a year on NAC compared with 1.71 on placebo, a difference with a p value of 0.019, and measures of small-airway function improved as well. The patients' scores on breathlessness, quality of life and a six-minute walk, however, did not separate from placebo, and no serious adverse events were recorded on treatment.
The definitive test came a year later. PANTHEON, published by Zheng and colleagues in The Lancet Respiratory Medicine in 2014, enrolled 1,006 patients aged 40 to 80 with moderate to severe COPD at 34 Chinese hospitals, who took either 600 mg twice daily or placebo for one year. Patients on placebo averaged about 1.49 exacerbations a year, and those on NAC averaged 1.16, a reduction of roughly 22 percent.
The benefit in PANTHEON was larger in patients with moderate disease, graded GOLD II, than in those with severe disease. Side effects were low and similar in both arms, which matters for a compound that patients would take every day for years.
The BRONCUS and PANTHEON results look contradictory until the regimens are set side by side. One trial gave 600 milligrams a day to European patients, many of them already on inhaled steroids, and the other gave 1,200 milligrams a day to Chinese patients with a different treatment background. NAC works partly as a raw material the body uses to build the antioxidant glutathione, and the question of how much reaches the airways has followed the compound through the respiratory literature.
Because the trials did not test the same question, reading them as a referendum on NAC in general misses what they actually support together, which is narrower and more useful: in COPD, the once-daily dose has a well-powered null result behind it, and the twice-daily dose has two positive randomized trials behind it, both run in China.
The other respiratory claim attached to NAC comes from a single winter in Italy. Silvio De Flora, Cesare Grassi and Luigi Carati published the trial in the European Respiratory Journal in 1997, after enrolling 262 people of both sexes at 20 Italian centers, most of them elderly, and excluding anyone with chronic respiratory disease.
Participants took either placebo or 600 milligrams of NAC twice daily for six months through the flu season. Among the patients who could be evaluated, 29 percent of those on NAC had an influenza-like episode, against 51 percent of those on placebo.
The more revealing number came from blood tests. Seroconversion to the A/H1N1 strain circulating that season occurred at similar rates in both groups, meaning NAC did not stop people from catching the virus, but it changed how many of the infected became ill: a quarter of the infected patients on NAC developed symptoms, compared with 79 percent of the infected patients on placebo.
That split comes from one trial run nearly three decades ago in an older population. It used the same 1,200-milligram daily total that worked in PANTHEON, which is the one consistent thread across the positive respiratory studies.
A typical capsule in an American store holds 600 milligrams, so the regimen that produced positive results in the lung trials means two capsules a day, spaced apart. The regimen most often printed on the bottle as a single daily serving matches the dose that BRONCUS tested for three years without benefit.
The populations matter as much as the dose. Every positive COPD trial enrolled people with diagnosed lung disease, and the flu trial enrolled mostly older adults, so none of these studies tested a healthy 30-year-old taking NAC to stay well through the office cold season, and the results cannot be stretched to cover that person.
Duration also shaped the findings. The COPD trials ran for a year or longer and counted flare-ups over that span, while the flu trial ran for six months, and a few weeks of capsules after a cough starts was not the question any of these teams asked.
For anyone with COPD or chronic bronchitis, the trials offer a concrete conversation with a clinician rather than a shopping decision. A patient can ask whether 1,200 milligrams a day fits alongside current inhalers and whether a moderate or severe diagnosis changes the expected benefit, and the same visit is the place to agree on how flare-ups will be tracked over a year, so the regimen can be judged on results.
That conversation matters because NAC in the United States is sold under supplement rules, and the quality of a given bottle is the buyer's problem to vet. A third-party testing seal and a clear milligram count per capsule are the minimum a shopper should expect before matching a label to a trial.
Across four trials and more than 1,900 patients, the record on NAC and lung health resolves into a dose pattern. At 600 milligrams once a day, the largest long-term European trial found no change in lung decline or flare-ups. At 600 milligrams twice a day, two Chinese trials found fewer exacerbations, and one Italian trial found fewer people sick with flu-like illness despite similar rates of infection.
The next useful trial would test the twice-daily dose in a population outside China, with modern inhaled therapy as the background, and it would settle whether PANTHEON's 22 percent travels. Until that study exists, the capsule count on the bottle is the detail most worth checking.